Patents by Inventor Manfred Wozny

Manfred Wozny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Erythropoietin conjugates
    Patent number: 7128913
    Abstract: The present invention refers to conjugates of erythropoietin with poly(ethylene glycol) comprising an erythropoietin glycoprotein having an N-terminal ?-amino group and having the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have the sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or a rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to one poly(ethylene glycol) group of the formula —CO—(CH2)x—(OCH2CH2)m—OR wherein the —CO of the poly(ethylene glycol) group forms an amide bond with said N-terminal ?-amino group; and wherein R is lower alkyl; x is 2 or 3; and m is from about 450 to about 1350.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: October 31, 2006
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Josef Burg, Alfred Engel, Reinhard Franze, Bernd Hilger, Hartmut Ernst Schurig, Wilhelm Tischer, Manfred Wozny
  • Erythropoietin conjugates
    Publication number: 20020115833
    Abstract: The present invention refers to conjugates of erythropoietin with poly(ethylene glycol) comprising an erythropoietin glycoprotein having an N-terminal &agr;-amino group and having the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have the sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or a rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to one poly(ethylene glycol) group of the formula
    Type: Application
    Filed: December 11, 2001
    Publication date: August 22, 2002
    Inventors: Josef Burg, Alfred Engel, Reinhard Franze, Bernd Hilger, Hartmut Ernst Schurig, Wilhelm Tischer, Manfred Wozny
  • Mutant of the Erythrina caffra type inhibitor and the use of the said mutant for purifying serine proteases
    Patent number: 5973118
    Abstract: A polypeptide which has the activity of an inhibitor DE-3 from Erythrina caffra and which reversibly and selectively binds serine proteases from a protein mixture is obtainable by culturing prokaryotic or eukaryotic host cells which have been transformed or transfected with a nucleic acid that codes for the said polypeptide in a manner that allows the host cells to express the said polypeptide under suitable nutrient conditions and isolating the said polypeptide, wherein the polypeptide has an amino acid sequence which is functionally analogous to SEQ ID NO:2, has a partial region that is more than 85% homologous to the region of amino acids 39-139 of this sequence, has two disulfide bridges and begins N-terminally with SEQ ID NO:4 or with a SEQ ID NO:4 extended N-terminally by methionine and has a binding capacity for tissue plasminogen activators of 1.25 MU/ml and more and is particularly suitable for purifying plasminogen activators such as tissue plasminogen activators (t-PA and derivatives).
    Type: Grant
    Filed: October 3, 1997
    Date of Patent: October 26, 1999
    Assignee: Roche Diagnostics GmbH
    Inventors: Ulrich Kohnert, Anne Stern, Manfred Wozny, Stephan Fischer